

Jupiter Neurosciences, Inc. (JUNS)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001679628

Jupiter Neurosciences, Inc.		
JUNS; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$5.6M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	late filer, thin data, degenerate inputs not computable: short runway, distress, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Apr 1, 2026 191 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026	
Last close	\$2.81 2026-10-08; market equity \$2.2M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Apr 1, 2026

other sections of this Annual Report on Form 10-K, includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data and we do not make any representation as to the accuracy of the information.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 50.1						
Gross profitability		0.3%	32.2%	92.5	372	2025-12-31

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(54.9%)	(6.6%)	7.8	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 1
Solvency, sleeve percentile 88.1						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(34.36)	(0.31)	83.4	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		0.65x	2.96x	92.8	839	2025-12-31
Growth and financing, sleeve percentile 50.9						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 1
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		not computable	2.1%			four annual observations are required; found 2
Net share issuance, one year		9.6%	2.5%	50.9	634	2026-03-31

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 2 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(97.3%)	8.0%	0
Distance from 52-week high	(97.8%)	(31.4%)	1
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	(0.17)	0.28	6
Sales to price	0.01	0.31	6
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(3.83)	(0.14)	0

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$150,166

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$17,565	2025-12-31	2026-04-01	10-K	0001493152-26-014687
2	assets	us-gaap:Assets	\$5.6M	2025-12-31	2026-04-01	10-K	0001493152-26-014687
3	net income	us-gaap:NetIncomeLoss	-\$8.6M	2025-12-31	2026-04-01	10-K	0001493152-26-014687
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$5.4M	2025-12-31	2026-04-01	10-K	0001493152-26-014687
5	assets	us-gaap:Assets	\$6.2M	2024-12-31	2026-04-01	10-K	0001493152-26-014687
6	current assets	us-gaap:AssetsCurrent	\$4.8M	2025-12-31	2026-04-01	10-K	0001493152-26-014687
7	current liabilities	us-gaap:LiabilitiesCurrent	\$7.4M	2025-12-31	2026-04-01	10-K	0001493152-26-014687
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$34.7M	2025-12-31	2026-04-01	10-K	0001493152-26-014687
9	operating income	us-gaap:OperatingIncomeLoss	-\$8.9M	2025-12-31	2026-04-01	10-K	0001493152-26-014687
10	book equity	us-gaap:StockholdersEquity	-\$1.8M	2025-12-31	2026-04-01	10-K	0001493152-26-014687
11	liabilities	us-gaap:Liabilities	\$7.4M	2025-12-31	2026-04-01	10-K	0001493152-26-014687
12	revenue	us-gaap:Revenues	\$21,796	2025-12-31	2026-04-01	10-K	0001493152-26-014687
13	shares outstanding	dei:EntityCommonStockSharesOutstanding	36,281,252	2026-03-31	2026-04-01	10-K	0001493152-26-014687
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	33,103,860	2025-03-28	2025-03-28	10-K	0001641172-25-001261